Hidenori Fujita - Concepedia

Author

Hidenori Fujita

Taiho Pharmaceutical (Japan)ORCID

Also Known As

H. FUJITA, H. Fujita, Hidenori Fujita

Publications

391

Citations

H-Index

Concepts

All Affiliations

Taiho Pharmaceutical (Japan)Cancer Research UK University of Cambridge Tokyo University of Agriculture and Technology

About

Hidenori Fujita is an author at Taiho Pharmaceutical (Japan) specializing in cell biology, medicine, and cancer genetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	75
2	Cell Biology	4	4	75
3	Health Sciences	1	1	11
4	Natural Sciences	1	1	10
5	Biochemistry	1	1	10

Hidenori Fujita

Publications

364

Citations

H-Index

Page 1

	Year	Citations
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, Cancer Research	2020	184
The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <i>In Vivo</i> Antitumor Properties and a Favorable Tolerability Profile Hidenori Fujita, Kazutaka Miyadera, Masanori Kato, Molecular Cancer Therapeutics	2013	37
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations Isao Miyazaki, Igor Odintsov, Keiji Ishida, Nature Cancer	2023	30
Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh, Molecular Cancer Therapeutics Abstract A270PathologyCellular PhosphorylationCancer BiologyTumor Biology	2013	28
The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer Kenta Watanabe, Michiko Hirata, Tsukasa Tominari, Journal of Biological Chemistry SclerostinBone Morphogenic ProteinFms-dependent Osteoclast DifferentiationOsteoporosisRadiation Oncology	2016	26
Epidemiologic survey of juvenile-onset insulin dependent diabetes mellitus (IDDM) in Hokkaido, Japan, 1973-1981. Nobuo Matsuura, Naoki Fukushima, Hidenori Fujita, The Tohoku Journal of Experimental Medicine	1983	19
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells Hidenori Fujita, Akira Gomori, Yayoi Fujioka, PLoS ONE	2016	19
Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors . Hiroshi Sootome, Yayoi Fujioka, Akihiro Miura, Molecular Cancer Therapeutics Tumor BiologyDrug ResistanceMolecular PharmacologyReceptor Tyrosine KinaseCancer Cell Biology	2013	11
Abstract P06-02: Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations Isao Miyazaki, Keiji Ishida, Masanori Kato, Molecular Cancer Therapeutics Crystal StructureMolecular BiologyTumor BiologyRet FusionMolecular Pharmacology	2021	10

Page 1